New Delhi [India], June 1 (ANI): Eli Lilly and Company India said on Tuesday it has received permission for restricted emergency use of its antibody drugs bamlanivimab 700 mg and etesevimab 1,400 mg in India for treatment of patients with mild to moderate coronavirus disease 2019 (Covid-19).
Lilly gets emergency use permission for its drugs to treat Covid
By IANS |
0 Views
MSN Labs inks deal with Lilly to launch baricitinib. Image Source: IANS News
New Delhi, June 1 : American pharmaceutical company Eli Lilly has announced that it has received permission for restricted emergency use of its antibody drugs, bamlanivimab 700mg and etesevimab 1400mg, in India for the treatment of patients with mild to moderate coronavirus disease.
Bamlanivimab and etesevimab together are indicated for restricted use in emergency situation, IV route for the treatment of mild to moderate coronavirus disease for injection administration in hospital settings.
The injection can be administered in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with RT-PCR positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19 and/or hospitalization and do not require oxygen.
Coronavirus | Eli Lilly India combination gets nod for emergency use
Updated:
Updated:
It could be used for treatment of mild to moderate COVID-19
Share Article
AAA
Eli Lilly and Company India on Tuesday said it has received permission for emergency use of its antibody drugs combination used for treatment of mild to moderate COVID-19.
| Photo Credit:
REUTERS
It could be used for treatment of mild to moderate COVID-19
Eli Lilly and Company India on Tuesday said it has received permission for emergency use of its antibody drugs combination used for treatment of mild to moderate COVID-19.
The company has received permission for restricted emergency use of its monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, used together for the treatment, it said in a statement.
Synopsis
Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Getty Images
Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of COVID-19 in India. The company said it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company. Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extrac
Updated:
Share Article
AAA Generic drugmaker BDR Pharma has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacturing and distribution of Baricitinib, a repurposed drug indicated in the treatment of COVID-19.
The collaboration will increase the availability of baricitinib in the country, a release from BDR Pharma said. The company has applied for restricted emergency use approval with the Drugs Controller General of India for baricitinib for COVID-19.
Chairman Dharmesh Shah sought to underscore the need to accelerate and harmonise production of drugs indicated in the treatment of COVID-19.
An oral medication registered in the country for treatment of moderate to severe active rheumatoid arthritis, Baricitinib received restricted emergency use approval, for use in combination with remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and paediatric patients 2